Renalytix shares fall 25% as revenues miss expectations Proactive uses images sourced from Shutterstock Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) shares dropped 25% to 4.25p after the company posted first-half revenues of $1.6 million and flagged slower-than-expected progress in rolling out its kidney disease diagnostic test. The company, which develops the FDA-approved and Medicare-reimbursed kidneyintelX.dkd test for early-stage diabetic kidney disease, said full-year revenue is now expected to reach ...

Core Insights - Renalytix plc has announced new pivotal data supporting kidneyintelX.dkd as a standard in precision medicine for chronic kidney disease (CKD) [1] - The company’s kidneyintelX.dkd is the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment in CKD [1] - A manuscript published in Diabetes Care highlights the association of kidneyintelX.dkd with kidney outcomes in the CANVAS and CREDENCE trials [1] Company Overview - Renalytix plc is focused on precision-medicine diagnostics specifically for kidney health [1] - The company has developed kidneyintelX.dkd, which is recognized for its role in early-stage CKD risk assessment [1] Industry Context - The publication of new data in a top-ranked diabetes journal emphasizes the importance of precision medicine in managing chronic kidney disease [1] - The involvement of leading nephrology and metabolism experts from the US, Europe, and Australia in the study underscores the global relevance of the findings [1]